WLF Seeking "Severe Sanctions" Against FDA

19 March 1997

The Washington Legal Foundation has asked the US District Court inWashington to impose severe sanctions against the US Food and Drug Administration, based on its "wilful and bad-faith" violations of court orders.

The motion stems from the FDA's violation of an order for then-FDA Commissioner David Kessler to appear for a deposition in connection with the WLF's First Amendment litigation against the FDA. Dr Kessler's refusal to appear has delayed progress in the case for over 10 months.

The suit is now bogged down with sanctions and depositions, says the WLF. Chief counsel Richard Stamp told the Marketletter that Dr Kessler had defied several court orders to appear for the deposition. In January, the WLF moved for sanctions, which would grant that a number of allegations in the suit, ie everything the WLF says about FDA policy, would be deemed to be true. A ruling on this request for sanctions is pending and, if granted, would eliminate a number of the factual issues in the litigation, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight